Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab Phase 3 Trial in Japan
jRCT2080225234Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of donanemab in central nervous system conditions (CNSD), sponsored by Eli Lilly and Company. Started Jun 2020; status: completed.
02
Drugs
donanemab
03
Conditions
central nervous system conditions (CNSD)
Beyond the preview
Go deeper on jRCT2080225234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225234.